Skip to content
ClinCalc Pro
Menu
Non-opioid Analgesic — Antipyretic Pregnancy: §4.6: 'A large amount of data on pregnant women indicate neither malformative, nor feto/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically needed, paracetamol can be used during pregnancy however it should be used at the lowest effective dose for the shortest possible time and at the lowest possible frequency.' Lactation: 'After oral administration, paracetamol is excreted into breast milk in small quantities. No undesirable effects on nursing infants have been reported. Consequently, Paracetamol may be used in breast-feeding women.'

Paracetamol IV (Orthopaedic — Opioid-Sparing)

Brand names: Perfalgan

Intravenous paracetamol is a non-opioid analgesic and antipyretic used as a baseline, opioid-sparing component of multimodal analgesia in orthopaedic patients who cannot take oral medication.

Adult dose

Dose: Patients weighing more than 50 kg: 1 g (100 ml of the 10 mg/ml solution) per administration. Patients weighing more than 33 kg up to 50 kg: 15 mg/kg per administration (1.5 ml/kg).
Route: Intravenous - 'Intravenous use. The paracetamol solution is administered as a 15-minute intravenous infusion.'
Frequency: 'The minimum interval between each administration must be at least 4 hours ... No more than 4 doses to be given in 24 hours.' In severe renal insufficiency 'the minimum interval between each administration ... must be at least 6 hours'.
Max: Maximum daily dose 4 g in patients over 50 kg with no additional risk factors for hepatotoxicity. Maximum daily dose 3 g in patients over 50 kg with additional risk factors for hepatotoxicity, and 'The maximum daily dose must not exceed 3000 mg' in adults with hepatocellular insufficiency, chronic alcoholism, chronic malnutrition (low reserves of hepatic glutathione) or dehydration. 'No more than 4 doses to be given in 24 hours.' The stated maximum daily dose 'is for patients that are not receiving other paracetamol containing products and should be adjusted accordingly taking such products into account.'
SCOPE: this is the whole of the adult regimen in the SPC for the intravenous product, which is this page's primary route. The SPC doses paracetamol infusion by BODY WEIGHT and risk factors only - it contains no orthopaedic-specific, opioid-sparing or multimodal-analgesia regimen, so no indication-specific dose is published. Posology table, verbatim: '> 50 kg with additional risk factors for hepatotoxicity 1 g 100 ml 100 ml 3 g'; '> 50 kg and no additional risk factors for hepatotoxicity 1 g 100 ml 100 ml 4 g'; '> 33 kg to <= 50 kg 15 mg/kg 1.5 ml/kg 75 ml 60 mg/kg not exceeding 3 g'. 'The dose to be administered and the bottle size to be used depend exclusively on the patient`s weight. The volume to be administered must not exceed the determined dose.' The 100 ml bottle 'is restricted to adults, adolescents and children weighing more than 33 kg'. RISK OF MEDICATION ERRORS (§4.4): 'Take care to avoid dosing errors due to confusion between milligram (mg) and milliliter (ml), which could result in accidental overdose and death'; 'When writing prescriptions, include both the total dose in mg and the total dose in volume.' The solution may be diluted 'up to one tenth (one volume Paracetamol into nine volumes diluent)'; if diluted, 'use the diluted solution within the hour following its preparation (infusion time included)'. Single use only; inspect visually and use 'only if solution is clear, colourless or slightly pinkish-orangish'.

Paediatric dose

Route: Intravenous 15-minute infusion. Patients weighing 10 kg or less: dose withdrawn from the 10 ml ampoule and diluted one volume paracetamol into nine volumes of sodium chloride 0.9% or glucose 5% before infusion.
Frequency: 'The minimum interval between each administration must be at least 4 hours' (at least 6 hours in severe renal insufficiency); 'No more than 4 doses to be given in 24 hours.'
Max: Maximum daily dose 2 g in patients over 10 kg to 33 kg or less, and 3 g in patients over 33 kg to 50 kg or less. 'No more than 4 doses to be given in 24 hours.' (For patients weighing 10 kg or less the SPC gives only a body-weight ceiling, quoted in the notes, and no absolute milligram ceiling.)
Concentration: 10 mg/ml
NOT A SINGLE PER-KG PER-DOSE FIGURE - dosePerKg is deliberately null because the SPC dose per administration changes across the weight bands (7.5 mg/kg at or below 10 kg, 15 mg/kg above 10 kg); do not calculate a weight-based dose from one number. §4.2 weight table, verbatim: '10 ml ampoule ... <= 10 kg* 7.5 mg/kg 0.75 ml/kg [maximum volume] 7.5 ml [maximum daily dose] 30 mg/kg'; '50 ml bottle ... > 10 kg to <= 33 kg 15 mg/kg 1.5 ml/kg 49.5 ml 60 mg/kg not exceeding 2 g'; '100 ml bottle ... > 33 kg to <= 50 kg 15 mg/kg 1.5 ml/kg 75 ml 60 mg/kg not exceeding 3 g'. Presentation is fixed by weight: 'The 10 ml ampoule is restricted to term newborn infants, infants and toddlers weighing up to 10 kg. The 50 ml bottle is restricted to toddlers and children weighing more than 10 kg and up to 33 kg. The 100 ml bottle is restricted to adults, adolescents and children weighing more than 33 kg.' '*Preterm newborn infants: No safety and efficacy data are available for premature newborn infants.' Patients weighing 10 kg or less: 'The volume to be administered should be withdrawn from the ampoule and diluted in a sodium chloride 9 mg/ml (0.9%) solution or glucose 50 mg/ml (5%) solution or a combination of both solutions up to one tenth (one volume Paracetamol into nine volumes diluent) and administered over 15 minutes'; 'A 5 or 10 ml syringe should be used ... However, this should never exceed 7.5 ml per dose'. 'The volume to be administered must not exceed the determined dose.' RISK OF MEDICATION ERRORS: 'Take care when prescribing and administering Paracetamol to avoid dosing errors due to confusion between milligram (mg) and millilitre (ml), which could result in accidental overdose and death ... When writing prescriptions, include both the total dose in mg and the total dose in volume.' Concentration is 10 mg/ml, stated verbatim in the product name and dosing table. Verify the paediatric dose against a children's formulary.

Dose adjustments

Renal

§4.2: 'Severe renal insufficiency: It is recommended, when giving paracetamol to patients with severe renal impairment (creatinine clearance <= 30 ml/min), to reduce the dose and increase the minimum interval between each administration to 6 hours.' 'The minimum interval between each administration in patients with severe renal insufficiency must be at least 6 hours.' §4.4 also lists severe renal insufficiency (creatinine clearance <= 30 ml/min) among the conditions requiring caution. No milligram reduction figure is given in the SPC.

Hepatic

'Cases of severe hepatocellular insufficiency' are an absolute contraindication (§4.3). §4.2: 'Adults with hepatocellular insufficiency, chronic alcoholism, chronic malnutrition (low reserves of hepatic glutathione), dehydration: The maximum daily dose must not exceed 3000 mg.' The posology table separately caps patients over 50 kg 'with additional risk factors for hepatotoxicity' at a maximum daily dose of 3 g (versus 4 g without such risk factors). §4.4 lists hepatocellular insufficiency, chronic alcoholism, chronic malnutrition and dehydration as cautions.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to paracetamol, propacetamol hydrochloride (prodrug of paracetamol) or to any of the excipients listed in section 6.1
  • Cases of severe hepatocellular insufficiency

Side effects

  • Thrombocytopenia, leucopenia, neutropenia (very rare, <1/10,000)
  • Hypersensitivity reaction (very rare) - 'ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment'
  • High anion gap metabolic acidosis due to pyroglutamic acidosis (metabolism and nutrition disorders)
  • Hypotension (rare); flushing (isolated cases)
  • Tachycardia (isolated cases)
  • Increased levels of hepatic transaminases (rare)
  • Serious skin reactions (very rare); pruritus and erythema (isolated cases)
  • Malaise (rare)
  • Injection site reactions - 'Frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation)'
  • Liver damage with doses higher than recommended - 'fulminant hepatitis, hepatic failure, cholestatic hepatitis, cytolytic hepatitis ... usually first seen after two days of drug administration with a peak seen, usually after 4 - 6 days' (§4.4)

Monitoring

  • 'In order to avoid the risk of overdose, check that other medicines administered do not contain either paracetamol or propacetamol' - the maximum daily dose in the posology table applies only to patients not receiving other paracetamol-containing products
  • 'If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended. The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors'
  • 'close monitoring is needed notably at the end of the infusion, regardless of administration route ... particularly for central route infusions, in order to avoid air embolism'
  • Watch for clinical signs and symptoms of liver damage, which are 'usually first seen after two days of drug administration with a peak seen, usually after 4 - 6 days'; 'Treatment with antidote should be given as soon as possible'
  • Review the need for the IV route daily - 'Prolonged or frequent use is discouraged. It is recommended that a suitable analgesic oral treatment will be used as soon as this route of administration is possible'

Clinical monograph

How it works

Its analgesic and antipyretic action is thought to be mediated centrally, including effects on prostaglandin pathways, with little peripheral anti-inflammatory activity.

Prescribing in practice

  • Dose by body weight and reduce in low-weight adults, hepatic impairment, malnutrition or chronic alcohol use to avoid hepatotoxicity, taking care to avoid duplicate paracetamol from other sources.
  • Administer as a slow infusion and check no other paracetamol-containing products are being given concurrently.
  • Used as the analgesic foundation, it reduces opioid requirements and associated adverse effects after orthopaedic surgery.

Monitoring

Monitor pain scores and cumulative paracetamol intake from all routes, with liver function review if overdose is suspected.

Counselling the patient

  • This is a regular background painkiller used to reduce the amount of strong opioid needed.
  • Tell the team about any paracetamol-containing tablets you take so doses are not duplicated.
  • Report ongoing pain so additional analgesia can be added.

Evidence & guidelines

Paracetamol is recommended as the foundation of multimodal, opioid-sparing analgesia in UK enhanced-recovery and perioperative guidance.

Reference: NICE NG124 (Hip Fracture); ERAS Society Orthopaedic Guidelines; Perfalgan SPC; MHRA Paracetamol Overdose Guidance; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.